260 related articles for article (PubMed ID: 22771878)
1. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
King V; Goldfarb SB; Brooks JD; Sung JS; Nulsen BF; Jozefara JE; Pike MC; Dickler MN; Morris EA
Radiology; 2012 Sep; 264(3):670-8. PubMed ID: 22771878
[TBL] [Abstract][Full Text] [Related]
2. Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI.
King V; Gu Y; Kaplan JB; Brooks JD; Pike MC; Morris EA
Eur Radiol; 2012 Dec; 22(12):2641-7. PubMed ID: 22752463
[TBL] [Abstract][Full Text] [Related]
3. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging.
King V; Kaplan J; Pike MC; Liberman L; David Dershaw D; Lee CH; Brooks JD; Morris EA
Breast J; 2012; 18(6):527-34. PubMed ID: 23002953
[TBL] [Abstract][Full Text] [Related]
4. Background parenchymal enhancement at breast MR imaging and breast cancer risk.
King V; Brooks JD; Bernstein JL; Reiner AS; Pike MC; Morris EA
Radiology; 2011 Jul; 260(1):50-60. PubMed ID: 21493794
[TBL] [Abstract][Full Text] [Related]
5. The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.
Price ER; Brooks JD; Watson EJ; Brennan SB; Comen EA; Morris EA
Eur Radiol; 2014 Jan; 24(1):162-8. PubMed ID: 23982290
[TBL] [Abstract][Full Text] [Related]
6. Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?
Dontchos BN; Rahbar H; Partridge SC; Korde LA; Lam DL; Scheel JR; Peacock S; Lehman CD
Radiology; 2015 Aug; 276(2):371-80. PubMed ID: 25965809
[TBL] [Abstract][Full Text] [Related]
7. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study.
Schrading S; Schild H; Kühr M; Kuhl C
Radiology; 2014 Apr; 271(1):45-55. PubMed ID: 24475835
[TBL] [Abstract][Full Text] [Related]
8. Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk?
Bermot C; Saint-Martin C; Malhaire C; Sebbag-Sfez D; Mouret-Fourme E; Carton M; Thibault FE
Eur J Radiol; 2018 Dec; 109():171-177. PubMed ID: 30527300
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
Wu S; Weinstein SP; DeLeo MJ; Conant EF; Chen J; Domchek SM; Kontos D
Breast Cancer Res; 2015 May; 17():67. PubMed ID: 25986460
[TBL] [Abstract][Full Text] [Related]
10. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Background Parenchymal Enhancement at Contrast-enhanced Spectral Mammography and Breast MR Imaging.
Sogani J; Morris EA; Kaplan JB; D'Alessio D; Goldman D; Moskowitz CS; Jochelson MS
Radiology; 2017 Jan; 282(1):63-73. PubMed ID: 27379544
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.
Leithner D; Baltzer PA; Magometschnigg HF; Wengert GJ; Karanikas G; Helbich TH; Weber M; Wadsak W; Pinker K
J Nucl Med; 2016 Oct; 57(10):1518-1522. PubMed ID: 27230924
[TBL] [Abstract][Full Text] [Related]
13. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
[TBL] [Abstract][Full Text] [Related]
14. Characteristics, Malignancy Rate, and Follow-up of BI-RADS Category 3 Lesions Identified at Breast MR Imaging: Implications for MR Image Interpretation and Management.
Chikarmane SA; Birdwell RL; Poole PS; Sippo DA; Giess CS
Radiology; 2016 Sep; 280(3):707-15. PubMed ID: 27089027
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Campos SM; Guastalla JP; Subar M; Abreu P; Winer EP; Cameron DA
Clin Breast Cancer; 2009 Feb; 9(1):39-44. PubMed ID: 19299239
[TBL] [Abstract][Full Text] [Related]
16. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
17. Comparison of contrast enhancement and diffusion-weighted magnetic resonance imaging in healthy and cancerous breast tissue.
Cho GY; Moy L; Kim SG; Klautau Leite AP; Baete SH; Babb JS; Sodickson DK; Sigmund EE
Eur J Radiol; 2015 Oct; 84(10):1888-93. PubMed ID: 26220915
[TBL] [Abstract][Full Text] [Related]
18. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
19. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
[TBL] [Abstract][Full Text] [Related]
20. Impact of fibroglandular tissue and background parenchymal enhancement on diffusion weighted imaging of breast lesions.
Iacconi C; Thakur SB; Dershaw DD; Brooks J; Fry CW; Morris EA
Eur J Radiol; 2014 Dec; 83(12):2137-2143. PubMed ID: 25445896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
